Artificial intelligence and systems biology analysis in stem cell research and therapeutics development
Stem Cells Translational Medicine · 28.09.2025 · 14 (10)
DOI: 10.1093/stcltm/szaf037 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Stem Cells Translational Medicine, online erschienen am 28.09.2025. Verfasst von Thayna Silva-Sousa und 22 weiteren Autor:innen. Beteiligte Einrichtung: BIH Center for Regenerative Therapies (BCRT), Charité Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health (BIH), B…. Hauptthemen laut MEDLINE: Artificial Intelligence, Systems Biology, Stem Cell Research, Stem Cells. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 276 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: German Federal Ministry for Education and Research, German Research Foundation.
Abstract (Originalsprache)
Background
Stem cell research has rapidly advanced during the past decades, but the translation into approved clinical products is still lagging behind. Multiple barriers to effective clinical translation exist. We hypothesize that an ineffective use of the existing wealth of data from both product development and clinical trials is a crucial barrier that hampers effective clinical implementation of stem cell therapies. Methods and Results: Here, we summarize the contribution of systems biology (SysBio) and artificial intelligence (AI) in stem cell research and therapy development, to better understand and overcome these barriers to effective clinical translation. Advancements in cell product profiling technology, clinical trial design, and adjunct clinical monitoring, offer new opportunities for a more integrated understanding of both, product and patient performance. Synergy of SysBioAI analysis is boosting a more rapid, integrated, and informative analysis of large‑scale multi‑omics data sets of patient and clinical trial outcomes, thus enabling the “Iterative Circle of Refined Clinical Translation”. This SysBioAI‑supported concept can assist more effective development and clinical use of stem cell therapeutics through iterative adaptation cycles. This includes product‑ and patient‑centered clinical safety and efficacy/potency evaluation through paired identification of suitable biomarkers of clinical response.
Conclusion
Integrated SysBioAI-use is a powerful tool to optimize the design and outcomes of clinical trials by identifying patient-specific responses, contributing to enhanced treatment safety and efficacy, and to spur new patient-centric and adaptable next-generation deep-medicine approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- BIH Center for Regenerative Therapies (BCRT), Charité Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health (BIH), Berlin 10117, Germany.
- Julius Wolff Institute (JWI), Charité Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health (BIH), Berlin 10117, Germany.
- Department of Vascular Surgery, Universitätsklinikum Ruppin-Brandenburg, Medizinische Hochschule Branderburg Theodor Fontane, Neuruppin 16816, Germany.
- Fakultät für Gesundheitswissenschaften Brandenburg, Gemeinsame Fakultät der Universität Potsdam, der Medizinischen Hochschule Brandenburg Theodor Fontane, und der Brandenburgischen Technischen Universität Cottbus-Senfte…
- Berlin Institute of Health (BIH), Charité Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health (BIH), Berlin 10117, Germany.
- Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo (USP), São Paulo, Brazil.
ORCID-Profile: Gabriela Riemekasten, Guido Moll
Förderung
- German Federal Ministry for Education and Research
- German Research Foundation
Zitieren
APA
Silva-Sousa, T., Nakanishi Usuda, J., Al-Arawe, N., Hinterseher, I., Catar, R., Luecht, C., Vallecillo Garcia, P., Riesner, K., Hackel, A., Schimke, L. F., Dutra Dias, H., Salerno Filgueiras, I., Nakaya, H. I., Camara, N. O. S., Fischer, S., Riemekasten, G., Ringdén, O., Penack, O., Winkler, T., …, & Moll, G. (2025). Artificial intelligence and systems biology analysis in stem cell research and therapeutics development. Stem Cells Translational Medicine, 14(10). https://doi.org/10.1093/stcltm/szaf037
Vancouver
Silva-Sousa T, Nakanishi Usuda J, Al-Arawe N, Hinterseher I, Catar R, Luecht C, et al. Artificial intelligence and systems biology analysis in stem cell research and therapeutics development. Stem Cells Translational Medicine. 2025;14(10). doi:10.1093/stcltm/szaf037
BibTeX
@article{SilvaSousa2025,
author = {Silva-Sousa, Thayna and Nakanishi Usuda, Júlia and Al-Arawe, Nada and Hinterseher, Irene and Catar, Rusan and Luecht, Christian and Vallecillo Garcia, Pedro and Riesner, Katarina and Hackel, Alexander and Schimke, Lena F and Dutra Dias, Haroldo and Salerno Filgueiras, Igor and Nakaya, Helder I and Camara, Niels Olsen Saraiva and Fischer, Stefan and Riemekasten, Gabriela and Ringdén, Olle and Penack, Olaf and Winkler, Tobias and Duda, Georg and Fonseca, Dennyson Leandro M and Cabral-Marques, Otávio and Moll, Guido},
title = {Artificial intelligence and systems biology analysis in stem cell research and therapeutics development},
journal = {Stem Cells Translational Medicine},
year = {2025},
volume = {14},
number = {10},
doi = {10.1093/stcltm/szaf037}
}
EUVIMED